De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Globus Medical Beheer

Beheer criteriumcontroles 4/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Dan Scavilla

Algemeen directeur

US$4.6m

Totale compensatie

Percentage CEO-salaris	10.2%
Dienstverband CEO	2.5yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	5.5yrs
Gemiddelde ambtstermijn bestuur	5.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Dan Scavilla's beloning veranderd ten opzichte van Globus Medical's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$41m
Mar 31 2024	n/a	n/a	US$67m
Dec 31 2023	US$5m	US$464k	US$123m
Sep 30 2023	n/a	n/a	US$158m
Jun 30 2023	n/a	n/a	US$204m
Mar 31 2023	n/a	n/a	US$201m
Dec 31 2022	US$4m	US$437k	US$190m
Sep 30 2022	n/a	n/a	US$155m
Jun 30 2022	n/a	n/a	US$155m
Mar 31 2022	n/a	n/a	US$142m
Dec 31 2021	US$2m	US$396k	US$149m
Sep 30 2021	n/a	n/a	US$187m
Jun 30 2021	n/a	n/a	US$184m
Mar 31 2021	n/a	n/a	US$122m
Dec 31 2020	US$2m	US$384k	US$102m
Sep 30 2020	n/a	n/a	US$95m
Jun 30 2020	n/a	n/a	US$89m
Mar 31 2020	n/a	n/a	US$148m
Dec 31 2019	US$2m	US$366k	US$155m
Sep 30 2019	n/a	n/a	US$146m
Jun 30 2019	n/a	n/a	US$143m
Mar 31 2019	n/a	n/a	US$150m
Dec 31 2018	US$2m	US$355k	US$156m
Sep 30 2018	n/a	n/a	US$144m
Jun 30 2018	n/a	n/a	US$134m
Mar 31 2018	n/a	n/a	US$118m
Dec 31 2017	US$1m	US$345k	US$107m

Compensatie versus markt: De totale vergoeding ($USD 4.56M ) Dan } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de MX markt ($USD 5.81M ).

Compensatie versus inkomsten: De vergoeding van Dan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Dan Scavilla (59 yo)

2.5yrs

Tenure

US$4,564,374

Compensatie

Mr. Daniel T. Scavilla, also known as Dan, serves as President and Chief Executive Officer at Globus Medical, Inc. since April 21, 2022 and serves as its Director since April 2022. He had been Executive Vi...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
David Paul	Co-Founder & Executive Chairman	21.8yrs	US$3.22m	16.44% MX$ 32.2b
Daniel Scavilla	President	2.5yrs	US$4.56m	geen gegevens
Keith Pfeil	CFO & COO	5.2yrs	US$2.06m	0% MX$ 0
Kelly Huller	Senior VP	5.8yrs	US$1.64m	0% MX$ 0
Brian Kearns	Senior Vice President of Business Development & Investor Relations	no data	geen gegevens	geen gegevens

5.5yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van GMED * is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
David Paul	Co-Founder & Executive Chairman	21.8yrs	US$3.22m	16.44% MX$ 32.2b
Daniel Scavilla	President	2.5yrs	US$4.56m	geen gegevens
Ann Rhoads	Independent Director	13.3yrs	US$490.69k	0.032% MX$ 62.1m
John DeFord	Independent Director	1.1yrs	US$276.27k	0.011% MX$ 22.6m
Stephen Zarrilli	Independent Director	5.4yrs	US$470.69k	0% MX$ 0
James Tobin	Independent Director	9.2yrs	US$478.19k	0% MX$ 0
Daniel Wolterman	Independent Director	1.1yrs	US$278.15k	0.018% MX$ 34.8m
Robert Douglas	Independent Director	4.8yrs	US$470.69k	0.0015% MX$ 2.9m
David Davidar	Independent Director	21.6yrs	US$468.19k	0.57% MX$ 1.1b
Leslie Norwalk	Independent Director	1.1yrs	US$278.77k	0.012% MX$ 23.8m
Daniel Lemaitre	Independent Director	13.5yrs	US$478.19k	0% MX$ 0

5.4yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van GMED * wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).

Globus Medical Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Independent Director recently sold Mex$12m worth of stock

Globus Medical, Inc., Annual General Meeting, Jun 05, 2024

Globus Medical Promotes Keith Pfeil to Chief Operating Officer

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Globus Medical, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Globus Medical, Inc. Launches the Next Wave of Orthopedic Trauma Solutions

Globus Medical, Inc. Launches ADIRA™? XLIF™? Plate System

Globus Medical, Inc. Revises Earnings Guidance for the Year 2024

Globus Medical, Inc. Receives FDA 510(k) Clearance for Excelsiusflex™? and ACTIFY™? 3D Total Knee System

Globus Medical, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 1000 Value-Defensive Index

Independent Director recently sold Mex$12m worth of stock

First quarter 2024 earnings released: US$0.053 loss per share (vs US$0.49 profit in 1Q 2023)

Globus Medical, Inc. Updates Earnings Guidance for the Full Year 2024

Globus Medical, Inc., Annual General Meeting, Jun 05, 2024

Globus Medical, Inc. to Report Q1, 2024 Results on May 07, 2024

Globus Medical, Inc. Reaffirms Revenue Guidance for the Full Year 2024

Globus Medical Promotes Keith Pfeil to Chief Operating Officer

Globus Medical, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Globus Medical, Inc. Revises Earnings Guidance for the Year 2023

Globus Medical, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Globus Medical, Inc. Updates Earnings Guidance for the Year 2023

Globus Medical, Inc. Announces Launch of the Marvel(Tm) Growing Rod System

Globus Medical, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 1000 Growth-Defensive Index

Insufficient new directors

Globus Medical, Inc. Provides Earnings Guidance for the Full Year 2023

Insufficient new directors

Full year 2022 earnings released: EPS: US$1.89 (vs US$1.48 in FY 2021)

Globus Medical, Inc. (NYSE:GMED) entered into a definitive agreement to acquire NuVasive, Inc. (NasdaqGS:NUVA) for $3.1 billion.

Globus Medical, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Insufficient new directors

Globus Medical, Inc. Reaffirms Net Sales Guidance for the Year 2022

Globus Medical, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Globus Medical, Inc. Reaffirms Sales Guidance for the Full Year 2022

Globus Medical, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Globus Medical, Inc. Announces First Surgeries Using Excelsius3D™

Globus Medical, Inc., Annual General Meeting, Jun 02, 2022

Globus Medical, Inc. to Report Q1, 2022 Results on May 10, 2022

Globus Medical, Inc. Provides Net Sales Guidance for the Full Year 2022

Globus Medical, Inc. to Report Q4, 2021 Results on Feb 17, 2022

Globus Medical, Inc. Announces First ExcelsiusGPS® Cranial Surgery

Globus Medical, Inc. Raises Earnings Guidance for the Full Year 2021

Globus Medical Announces Completion of 20,000 Procedures Utilizing ExcelsiusGPS®

First quarter 2021 earnings released: EPS US$0.45 (vs US$0.26 in 1Q 2020)

Globus Medical, Inc. Raises Earnings Guidance for the Full Year 2021

Full year 2020 earnings released

Revenue beats expectations

Globus Medical, Inc. to Report Q4, 2020 Results on Feb 17, 2021

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 2000 Defensive Index

Globus Medical, Inc. Wins Group Purchasing Agreement with Premier

Globus Medical, Inc. to Report Q3, 2020 Results on Oct 28, 2020

Northwest Specialty Hospital Partners with Globus Medical, Inc to Implement the First Fully Navigated Spinal Surgery for Minimally Invasive Interbody Spine Fusion Procedures

Globus Medical, Inc. (NYSE:GMED) acquired Synoste Oy for $33.3 million.

Globus Medical, Inc. Withdrew Previously Announce Full Year 2020 Guidance

Earnings released

Globus Medical, Inc. to Report Q2, 2020 Results on Aug 05, 2020

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 2000 Defensive Index

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 2500 Growth Index

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 2000 Index

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd